A leading Welsh innovator in healthcare technology is celebrating once again after its innovative non-invasive blood glucose ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Patients who received Lilly’s pill did not show signs of liver damage, the company said. Liver side effects scuttled Pfizer’s ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Scared of needles but intrigued by injectable drugs that help manage blood sugar levels? You'll be happy to know Eli Lilly ...

Eli Lilly’s recent announcement of the success of its daily obesity pill, orforglipron, in the first late-stage trial has generated significant buzz in the pharmaceutical industry. The trial, which ...